T-REGULATORY CELL KINETICS FOR PATIENTS RECEIVING ALEMTUZUMAB AND UNDERGOING STEM CELL TRANSPLANTATION FROM HLA MISMATCHED-RELATED OR ONE ANTIGEN MISMATCHED-UNRELATED DONORS.

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Cytarabine; Mesna; Methotrexate; Tacrolimus; Tacrolimus
Indications Graft-versus-host disease; Hodgkin's disease; Leukaemia; Lymphoma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma
Focus Therapeutic Use
Acronyms REGALE

01 May 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
30 Mar 2013 Planned End Date changed from 1 Dec 2015 to 1 May 2013 as reported by ClinicalTrials.gov.
30 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com